IMRN vs PHAR
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMRN is a StrongBuy and PHAR is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMRN’s FA Score shows that 1 FA rating(s) are green whilePHAR’s FA Score has 1 green FA rating(s).
- IMRN’s FA Score: 1 green, 4 red.
- PHAR’s FA Score: 1 green, 4 red.
Price Growth
IMRN (@Biotechnology) experienced а -1.06% price change this week, while PHAR (@Biotechnology) price change was +2.56% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -3.88%. For the same industry, the average monthly price growth was +15.29%, and the average quarterly price growth was -13.75%.
Reported Earning Dates
IMRN is expected to report earnings on May 28, 2025.
PHAR is expected to report earnings on Jul 31, 2025.
Industries' Descriptions
@Biotechnology (-3.88% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| IMRN | PHAR | IMRN / PHAR | |
| Capitalization | 10.4M | 592M | 2% |
| EBITDA | -7.35M | 7.56M | -97% |
| Gain YTD | 9.412 | -10.581 | -89% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 6.54M | 286M | 2% |
| Total Cash | 7.74M | 172M | 4% |
| Total Debt | N/A | 127M | - |
IMRN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 5 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 94 | |
PRICE GROWTH RATING 1..100 | 53 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 55 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| RSI ODDS (%) |
| Stochastic ODDS (%) |
| Momentum ODDS (%) |
| MACD ODDS (%) |
| TrendWeek ODDS (%) |
| TrendMonth ODDS (%) |
| Advances ODDS (%) |
| Declines ODDS (%) |
| BollingerBands ODDS (%) |
| Aroon ODDS (%) |
PHAR and
Correlation & Price change
A.I.dvisor tells us that PHAR and APLM have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PHAR and APLM's prices will move in lockstep.
| Ticker / NAME | Correlation To PHAR | 1D Price Change % | ||
|---|---|---|---|---|
| PHAR | 100% | -0.50% | ||
| APLM - PHAR | 31% Poorly correlated | -4.60% | ||
| ADPT - PHAR | 27% Poorly correlated | N/A | ||
| IBRX - PHAR | 27% Poorly correlated | -5.97% | ||
| ATXS - PHAR | 26% Poorly correlated | +1.14% | ||
| SONN - PHAR | 25% Poorly correlated | -2.27% | ||
More | ||||